2 Obamacare Prescription Drug Assistance Programs Ending: What You Need to Know

Last week, prescription drug maker giants Merck  (NYSE: MRK  ) and GlaxoSmithKline (NYSE: GSK  ) announced that they would stop offering prescription drug co-pay assistance to people who had purchased insurance plans on the exchanges created by the Affordable Care Act, also known as Obamacare.

Insurers and prescription benefit managers (or PBMs) often use higher co-pays to discourage consumers from purchasing the more expensive branded drug when a cheaper generic version is available. Big pharma companies like Merck, GlaxoSmithKline, Sanofi (NYSE: SNY  )  Eli Lilly (NYSE: LLY  ) , and Novartis (NYSE: NVS  ) have responded by offering co-pay assistance (often in the form of coupons) to make the branded version equally cheap for the end consumer. But that practice may now be under threat among plans purchased on the Obamacare exchanges.

There is confusion regarding whether Obamacare insurance plans fall under regulations that ban co-pay assistance from drugmakers for Medicare and Medicaid members but have not thus far applied to private insurance. HHS Secretary Kathleen Sebelius, who has overseen the entire Obamacare rollout, and the Centers for Medicare & Medicaid Services, which run the federal exchanges where consumers have purchased insurance, have issued seemingly contradictory guidance, leading to confusion and concern throughout the pharmaceutical sector.

In this segment from Thursday's Market Checkup, Motley Fool health care analysts David Williamson and Michael Douglass discuss these developments and what they mean for consumers and your investments in these major drug companies.

Worried about Obamacare? Take advantage of this little-known government tax rule
Recent tax increases have affected nearly every American taxpayer. But with the right planning, you can take steps to take control of your taxes and potentially even lower your tax bill. In our brand-new special report "The IRS Is Daring You to Make This Investment Now!," you'll learn about the simple strategy to take advantage of a little-known IRS rule. Don't miss out on advice that could help you cut taxes for decades to come. Click here to learn more.

Read/Post Comments (2) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2896004, ~/Articles/ArticleHandler.aspx, 9/2/2015 4:49:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Michael Douglass

As the Motley Fool's Health Care Editor/Analyst, I focus on all things health care -- although my greatest interest is in the megatrends reshaping the American health care system, including the Affordable Care Act, Accountable Care Organizations, a shifting regulatory landscape, and the new drug discoveries fundamentally changing disease management and treatment.

Today's Market

updated 7 hours ago Sponsored by:
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASD 4,636.11 -140.40 -2.94%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 4:01 PM
GSK $39.47 Down -1.46 -3.57%
GlaxoSmithKline CAPS Rating: ****
LLY $79.80 Down -2.55 -3.10%
Eli Lilly & Co. CAPS Rating: ****
MRK $52.53 Down -1.32 -2.45%
Merck & Co., Inc. CAPS Rating: ****
NVS $94.68 Down -2.54 -2.61%
Novartis CAPS Rating: ****
SNY $48.11 Down -0.81 -1.66%
Sanofi (ADR) CAPS Rating: *****